Scores by kind of claim
Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.
-
Factual claims
Statements about the present or the past, checked against the record: did they hold up?
75 61 88 -
Predictions
Statements about events outside the person's control, checked once they fell due: did they come true?
Insufficient record: 2 predictions resolved, 5 needed for a score.
All types combined: 75 (likely 61 to 88, low confidence), from 12 claims: 12 factual claims. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.
Jim Cramer's claims
“You don't buy the stock of Lilly here — the stock jumped nearly 15% yesterday, for heaven's sake.”
Jim Cramer, CNBC host 9 August 2023 Cramer says investors need to buy stock before its big move, not after (CNBC)
Eli Lilly's stock jumped nearly 15% on the trading day before 2023-08-09.
Resolved true The record shows it happened or was so.
What would count as true or false
Judge Eli Lilly's (LLY) close-to-close percentage change on 2023-08-08, the trading day before 2023-08-09. True: a gain of about 13.5% to 15.5%. Mostly true: a gain of 12% to under 13.5%, or above 15.5% up to 17%, or the gain was about 15% but on a different nearby day. Mostly false: a gain of 8% to under 12%, or above 17%. False: a gain under 8%, or a decline.
Evidence
- Lilly (Eli) (LLY) — Earnings History & Price Movement wsfriend.com
“Its largest post-earnings gain was +14.87% (Aug 08, 2023) and its largest decline was -14.14% (Aug 07, 2025).”
- Lilly market value soars on higher sales, obesity drug potential BioPharma Dive · 8 August 2023
“Shares jumped 15% on second quarter earnings that showed the company’s revenue rose by 28%, driven by fast sales of its diabetes medicine Mounjaro.”
- Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap Zacks Investment Research (via TradingView) · 9 August 2023
“The stock soared 15% to heights not seen since the early 2000s, adding $64 billion to its market cap.”
Reasoning
E1 records Eli Lilly's largest post-earnings gain as +14.87% on Aug 08, 2023. That falls within the 13.5%–15.5% range the criteria set for a true verdict. E2 (dated 2023-08-08) and E3 (dated 2023-08-09) are both independent, and each reports that the shares jumped or soared about 15% on second-quarter earnings. Together the three sources show a gain of nearly 15% on 2023-08-08.
Cite this claim
Jim Cramer, “Eli Lilly's stock jumped nearly 15% on the trading day before 2023-08-09.” (said 9 August 2023). Verdict: resolved true. Reliability API, claim c_2b027ba25a68, method 0.1.0+c876030c. https://epistacklabs.com/claims/c_2b027ba25a68
Claims without a verdict
Is a verdict here wrong, or do you speak for Jim Cramer? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.